Literature DB >> 22543872

Mouse models of SMA: tools for disease characterization and therapeutic development.

Thomas W Bebee1, Catherine E Dominguez, Dawn S Chandler.   

Abstract

Mouse models of human disease are an important tool for studying disease mechanism and manifestation in a way that is physiologically relevant. Spinal muscular atrophy (SMA) is a neurodegenerative disease that is caused by deletion or mutation of the survival motor neuron gene (SMN1). The SMA disease is present in a spectrum of disease severities ranging from infant mortality, in the most severe cases, to minor motor impairment, in the mildest cases. The variability of disease severity inversely correlates with the copy number, and thus expression of a second, partially functional survival motor neuron gene, SMN2. Correspondingly, a plethora of mouse models has been developed to mimic these different types of SMA. These models express a range of SMN protein levels and extensively cover the severe and mild types of SMA, with neurological and physiological manifestation of disease supporting the relevance of these models. The SMA models provide a strong background for studying SMA and have already shown to be useful in pre-clinical therapeutic studies. The purpose of this review is to succinctly summarize the genetic and disease characteristic of the SMA mouse models and to highlight their use for therapeutic testing.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22543872     DOI: 10.1007/s00439-012-1171-5

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  92 in total

1.  A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients.

Authors:  K Zerres; S Rudnik-Schöneborn; E Forrest; A Lusakowska; J Borkowska; I Hausmanowa-Petrusewicz
Journal:  J Neurol Sci       Date:  1997-02-27       Impact factor: 3.181

Review 2.  Spinal muscular atrophy--clinical and genetic correlations.

Authors:  K Zerres; B Wirth; S Rudnik-Schöneborn
Journal:  Neuromuscul Disord       Date:  1997-05       Impact factor: 4.296

3.  Identification of proximal spinal muscular atrophy carriers and patients by analysis of SMNT and SMNC gene copy number.

Authors:  P E McAndrew; D W Parsons; L R Simard; C Rochette; P N Ray; J R Mendell; T W Prior; A H Burghes
Journal:  Am J Hum Genet       Date:  1997-06       Impact factor: 11.025

4.  A single administration of morpholino antisense oligomer rescues spinal muscular atrophy in mouse.

Authors:  Paul N Porensky; Chalermchai Mitrpant; Vicki L McGovern; Adam K Bevan; Kevin D Foust; Brain K Kaspar; Stephen D Wilton; Arthur H M Burghes
Journal:  Hum Mol Genet       Date:  2011-12-20       Impact factor: 6.150

5.  SMN deficiency disrupts brain development in a mouse model of severe spinal muscular atrophy.

Authors:  Thomas M Wishart; Jack P-W Huang; Lyndsay M Murray; Douglas J Lamont; Chantal A Mutsaers; Jenny Ross; Pascal Geldsetzer; Olaf Ansorge; Kevin Talbot; Simon H Parson; Thomas H Gillingwater
Journal:  Hum Mol Genet       Date:  2010-08-12       Impact factor: 6.150

6.  Delivery of recombinant follistatin lessens disease severity in a mouse model of spinal muscular atrophy.

Authors:  Ferrill F Rose; Virginia B Mattis; Hansjörg Rindt; Christian L Lorson
Journal:  Hum Mol Genet       Date:  2008-12-12       Impact factor: 6.150

7.  Trans-splicing-mediated improvement in a severe mouse model of spinal muscular atrophy.

Authors:  Tristan H Coady; Christian L Lorson
Journal:  J Neurosci       Date:  2010-01-06       Impact factor: 6.167

8.  Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy.

Authors:  Amy M Avila; Barrington G Burnett; Addis A Taye; Francesca Gabanella; Melanie A Knight; Parvana Hartenstein; Ziga Cizman; Nicholas A Di Prospero; Livio Pellizzoni; Kenneth H Fischbeck; Charlotte J Sumner
Journal:  J Clin Invest       Date:  2007-02-22       Impact factor: 14.808

9.  A negatively acting bifunctional RNA increases survival motor neuron both in vitro and in vivo.

Authors:  Alexa Dickson; Erkan Osman; Christian L Lorson
Journal:  Hum Gene Ther       Date:  2008-11       Impact factor: 4.793

10.  A transgene carrying an A2G missense mutation in the SMN gene modulates phenotypic severity in mice with severe (type I) spinal muscular atrophy.

Authors:  Umrao R Monani; Matthew T Pastore; Tatiana O Gavrilina; Sibylle Jablonka; Thanh T Le; Catia Andreassi; Jennifer M DiCocco; Christian Lorson; Elliot J Androphy; Michael Sendtner; Michael Podell; Arthur H M Burghes
Journal:  J Cell Biol       Date:  2003-01-06       Impact factor: 10.539

View more
  26 in total

Review 1.  Spinal muscular atrophy: an update on therapeutic progress.

Authors:  Joonbae Seo; Matthew D Howell; Natalia N Singh; Ravindra N Singh
Journal:  Biochim Biophys Acta       Date:  2013-08-27

2.  Splicing regulation in spinal muscular atrophy by an RNA structure formed by long-distance interactions.

Authors:  Natalia N Singh; Brian M Lee; Ravindra N Singh
Journal:  Ann N Y Acad Sci       Date:  2015-02-27       Impact factor: 5.691

3.  Spinal muscular atrophy astrocytes exhibit abnormal calcium regulation and reduced growth factor production.

Authors:  Jered V McGivern; Teresa N Patitucci; Joshua A Nord; Marie-Elizabeth A Barabas; Cheryl L Stucky; Allison D Ebert
Journal:  Glia       Date:  2013-07-10       Impact factor: 7.452

Review 4.  Developing therapies for spinal muscular atrophy.

Authors:  Mary H Wertz; Mustafa Sahin
Journal:  Ann N Y Acad Sci       Date:  2015-07-14       Impact factor: 5.691

Review 5.  RNA Splicing and Disease: Animal Models to Therapies.

Authors:  Matías Montes; Brianne L Sanford; Daniel F Comiskey; Dawn S Chandler
Journal:  Trends Genet       Date:  2018-11-19       Impact factor: 11.639

Review 6.  Diverse role of survival motor neuron protein.

Authors:  Ravindra N Singh; Matthew D Howell; Eric W Ottesen; Natalia N Singh
Journal:  Biochim Biophys Acta Gene Regul Mech       Date:  2017-01-15       Impact factor: 4.490

Review 7.  Mechanistic principles of antisense targets for the treatment of spinal muscular atrophy.

Authors:  Natalia N Singh; Brian M Lee; Christine J DiDonato; Ravindra N Singh
Journal:  Future Med Chem       Date:  2015-09-18       Impact factor: 3.808

Review 8.  Genetically modified pigs to model human diseases.

Authors:  Tatiana Flisikowska; Alexander Kind; Angelika Schnieke
Journal:  J Appl Genet       Date:  2014-02       Impact factor: 3.240

9.  SMA valiant trial: a prospective, double-blind, placebo-controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy.

Authors:  John T Kissel; Bakri Elsheikh; Wendy M King; Miriam Freimer; Charles B Scott; Stephen J Kolb; Sandra P Reyna; Thomas O Crawford; Louise R Simard; Kristin J Krosschell; Gyula Acsadi; Mary K Schroth; Guy D'Anjou; Bernard LaSalle; Thomas W Prior; Susan Sorenson; Jo Anne Maczulski; Kathryn J Swoboda
Journal:  Muscle Nerve       Date:  2014-02       Impact factor: 3.217

10.  The motor neuron response to SMN1 deficiency in spinal muscular atrophy.

Authors:  Peter B Kang; Clifton L Gooch; Michael P McDermott; Basil T Darras; Richard S Finkel; Michele L Yang; Douglas M Sproule; Wendy K Chung; Petra Kaufmann; Darryl C de Vivo
Journal:  Muscle Nerve       Date:  2014-05       Impact factor: 3.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.